Epigenetics in Atrial Fibrillation: Molecular Mechanisms and Therapeutic Avenues
Reviews in Cardiovascular Medicine · 16.07.2026 · 27 (7)
DOI: 10.31083/rcm49551 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 16.07.2026. Verfasst von Xinyi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the First College of Clinical Medical Sciences, China Three Gorges University, 443003 Yichang, Hubei, China. Die Arbeit nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Major Project of China, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Atrial fibrillation (AF) represents the most common sustained cardiac arrhythmia in clinical practice and imposes a growing global disease burden. However, current therapeutic strategies remain considerably limited in efficacy, durability, and safety. Recently, the role of epigenetic mechanisms in the pathogenesis of AF, as key regulators of atrial structural and electrical remodeling, has garnered considerable attention. This review systematically elucidates the central role of multiple epigenetic regulatory mechanisms, including deoxyribonucleic acid (DNA) methylation, histone modifications, non-coding ribonucleic acids (RNAs) (microRNAs, long non-coding RNAs, circular RNAs, and transfer RNA-derived small RNAs), chromatin remodeling, and RNA methylation, in the atrial structural and electrical remodeling underlying AF. These reversible molecular modifications are widely implicated in the pathophysiological processes of AF through the regulation of key gene expression. In addition, circulating epigenetic markers (e.g., methylated DNA fragments and specific miRNAs) show substantial potential as biomarkers for AF diagnosis, risk stratification, and relapse prediction. Furthermore, targeted epigenetic intervention strategies (e.g., histone deacetylase (HDAC) inhibitors, demethylating agents) offer novel avenues for the precision therapy of AF. Thus, this review seeks to comprehensively summarize recent advances in the epigenetic regulation of AF pathogenesis, provide a theoretical basis for an in-depth understanding of the underlying mechanisms, and inform the development of innovative preventive and therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, the First College of Clinical Medical Sciences, China Three Gorges University, 443003 Yichang, Hubei, China.
- Hubei Key Laboratory of Ischemic Cardiovascular Disease, 443003 Yichang, Hubei, China.
- Hubei Provincial Clinical Research Center for Ischemic Cardiovascular Disease, 443003 Yichang, Hubei, China.
ORCID-Profile: Xinyi Liu, Chaojun Yang, Yifan Huang, Bingxun Li, Jian Yang, Zhixing Fan
Förderung
- National Science and Technology Major Project of China
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- Health Commission of Hubei Province Project
Zitieren
APA
Liu, X., Yang, C., Huang, Y., Li, B., Yang, J., & Fan, Z. (2026). Epigenetics in Atrial Fibrillation: Molecular Mechanisms and Therapeutic Avenues. Reviews in Cardiovascular Medicine, 27(7). https://doi.org/10.31083/rcm49551
Vancouver
Liu X, Yang C, Huang Y, Li B, Yang J, Fan Z. Epigenetics in Atrial Fibrillation: Molecular Mechanisms and Therapeutic Avenues. Reviews in Cardiovascular Medicine. 2026;27(7). doi:10.31083/rcm49551
BibTeX
@article{Liu2026,
author = {Liu, Xinyi and Yang, Chaojun and Huang, Yifan and Li, Bingxun and Yang, Jian and Fan, Zhixing},
title = {Epigenetics in Atrial Fibrillation: Molecular Mechanisms and Therapeutic Avenues},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
volume = {27},
number = {7},
doi = {10.31083/rcm49551}
}
EUVIMED